Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Drugs & Targets

FDA approves Lumisight to assist breast cancer detection

April 19, 2024
Vol.50 No.16
Drugs & Targets

FDA grants accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors

April 12, 2024
Vol.50 No.15
White House misses deadline to finalize FDA rule banning menthol cigarettes, prompting lawsuit from health groups
White House

White House misses deadline to finalize FDA rule banning menthol cigarettes, prompting lawsuit from health groups

April 05, 2024
Vol.50 No.14
By Jacquelyn Cobb
Drugs & Targets

FDA approves Abecma for earlier lines of treatment for MM

April 05, 2024
Vol.50 No.14
Exercising new powers, FDA issues Complete Response Letters based on insufficient enrollment in confirmatory trials
Regulatory News

Exercising new powers, FDA issues Complete Response Letters based on insufficient enrollment in confirmatory trials

March 29, 2024
Vol.50 No.13
By Paul Goldberg
Drugs & Targets

FDA approves Elahere for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

March 29, 2024
Vol.50 No.13
Drugs & Targets

FDA grants orphan drug designation to Heidelberg Pharma agent for MM

March 29, 2024
Vol.50 No.13
ODAC votes in favor of two CAR T-cell therapies for MM after weighing FDA concerns about early deaths
Regulatory News

ODAC votes in favor of two CAR T-cell therapies for MM after weighing FDA concerns about early deaths

March 22, 2024
Vol.50 No.12
By Jacquelyn Cobb and Paul Goldberg
Drugs & Targets

FDA grants accelerated approval to Iclusig + chemotherapy for newly diagnosed Ph+ ALL

March 22, 2024
Vol.50 No.12
Drugs & Targets

FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products

March 22, 2024
Vol.50 No.12

Posts navigation

Previous1…353637…61Next

Trending Stories

  • As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
    The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded
  • Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
    “The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”
  • Peter F. Garrett to people with cancer: Your story has power
  • Lessons from the AIDS Quilt: what the cancer world can learn from AIDS advocacy
  • Survivorship begins at diagnosis—cancer care system must recognize this
  • House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account